The Influence of Menopausal Hormone Therapy and Potential Lifestyle Interactions in Female Cancer Development—a Population-Based Prospective Study

  • Marianne Holm
  • Anja Olsen
  • Cecilie Kyrø
  • Kim Overvad
  • Niels Kroman
  • Anne Tjønneland
Original Paper

Abstract

The past decades have seen contradictory research results on the health benefits and risks of menopausal hormone therapy (HT). In particular, long-term associations with overall cancer incidence and the potential interplay with other lifestyle factors remain undetermined. In a population-based prospective cohort, 29,152 women aged 50–64 years at entry (1993–1997) were followed through 2013 for incidence of cancer (99% complete follow-up). Cox’ proportional hazards models were used to estimate cancer incidence according to baseline HT alone and in combination with lifestyle factors including alcohol intake, BMI, physical activity, diet, and smoking. Among 5484 women diagnosed with cancer, baseline HT was associated with an overall higher risk of cancer (HR 1.28; 95%CI, 1.21–1.36)—in particular, a higher risk of breast (HR 1.77; 95%CI, 1.61–1.95), ovarian (HR 1.68; 95%CI, 1.26–2.26), and endometrial (HR 1.86; 95%CI, 1.45–2.37) cancer. Combination with other lifestyle risk factors largely displayed additive associations. The risk of colorectal cancer was significantly lower (HR 0.79; 95%CI, 0.66–0.95). However, in the interaction analysis, only “healthy” subgroups of women using HT had a lower risk of colorectal cancer. With an overall higher risk of cancer among women on HT, this study underlined the importance of considering all female cancer risks in menopausal treatment guidelines. The largely additive associations between HT and the investigated lifestyle factors support the notion that high levels of hormones in itself play an important etiological role in female reproductive cancers, whereas the possible protective impact in colorectal cancer might be limited to women with an otherwise healthy lifestyle.

Abbreviations

95%CI

95% confidence interval

BMI

Body mass index

HR

Hazard ratio

HT

Hormone therapy

Supplementary material

12672_2018_338_MOESM1_ESM.docx (17 kb)
ESM 1 (DOCX 16 kb)

References

  1. 1.
    Nelson HD (2008) Menopause. Lancet 371(9614):760–770CrossRefPubMedGoogle Scholar
  2. 2.
    Sarrel P, Portman D, Lefebvre P, Lafeuille MH, Grittner AM, Fortier J, Gravel J, Duh MS, Aupperle PM (2015) Incremental direct and indirect costs of untreated vasomotor symptoms. Menopause (New York, NY) 22(3):260–266CrossRefGoogle Scholar
  3. 3.
    Maclennan AH, Broadbent JL, Lester S, Moore V (2004) Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. The Cochrane Database Syst Rev 18(4):Cd002978Google Scholar
  4. 4.
    Friis S, Kesminiene A, Espina C, Auvinen A, Straif K, Schuz J (2015) European Code against Cancer 4th Edition: medical exposures, including hormone therapy, and cancer. Cancer Epidemiol 39 Suppl 1:S107-19Google Scholar
  5. 5.
    Chlebowski RT, Rohan TE, Manson JE, Aragaki AK, Kaunitz A, Stefanick ML, Simon MS, Johnson KC, Wactawski-Wende J, O'Sullivan MJ et al (2015) Breast cancer after use of estrogen plus progestin and estrogen alone: analyses of data from 2 Women’s Health Initiative randomized clinical trials. JAMA Oncol 1(3):296–305CrossRefPubMedGoogle Scholar
  6. 6.
    Chlebowski RT, Anderson GL (2014) Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids 90:53–59CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Sjogren LL, Morch LS, Lokkegaard E (2016) Hormone replacement therapy and the risk of endometrial cancer: a systematic review. Maturitas 91:25–35CrossRefPubMedGoogle Scholar
  8. 8.
    Sarri G, Davies M, Lumsden MA, Guideline Development G (2015) Diagnosis and management of menopause: summary of NICE guidance. Br Med J (Clin Res Ed) 351:h5746Google Scholar
  9. 9.
    The North American Menopause Society (2017) The 2017 hormone therapy position statement of the North American Menopause Society. Menopause (New York, NY) 24(7):728–753CrossRefGoogle Scholar
  10. 10.
    Beral V, Gaitskell K, Hermon C, Moser K, Reeves G, Peto R (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385(9980):1835–1842CrossRefPubMedGoogle Scholar
  11. 11.
    Shi LF, Wu Y, Li CY (2016) Hormone therapy and risk of ovarian cancer in postmenopausal women: a systematic review and meta-analysis. Menopause (New York, NY) 23(4):417–424Google Scholar
  12. 12.
    Green J, Czanner G, Reeves G, Watson J, Wise L, Roddam A, Beral V (2012) Menopausal hormone therapy and risk of gastrointestinal cancer: nested case-control study within a prospective cohort, and meta-analysis. Int J Cancer 130(10):2387–2396CrossRefPubMedGoogle Scholar
  13. 13.
    Manson JE (2013) The role of personalized medicine in identifying appropriate candidates for menopausal estrogen therapy. Metab Clin Exp 62(Suppl 1):S15–S19CrossRefPubMedGoogle Scholar
  14. 14.
    World Cancer Research Fund (2017) Cancer prevention & survival summary of global evidence on diet, weight, physical activity & what increases or decreases your risk of cancer. In: Continuous update project report. May 2017 ednGoogle Scholar
  15. 15.
    Leon ME, Peruga A, McNeill A, Kralikova E, Guha N, Minozzi S, Espina C, Schuz J (2015) European Code against Cancer, 4th edition: tobacco and cancer. Cancer Epidemiol 39(Suppl 1):S20–S33CrossRefPubMedGoogle Scholar
  16. 16.
    Kendall A, Folkerd EJ, Dowsett M (2007) Influences on circulating oestrogens in postmenopausal women: relationship with breast cancer. J Steroid Biochem Mol Biol 103(2):99–109CrossRefPubMedGoogle Scholar
  17. 17.
    Tjonneland A, Olsen A, Boll K, Stripp C, Christensen J, Engholm G, Overvad K (2007) Study design, exposure variables, and socioeconomic determinants of participation in diet, cancer and health: a population-based prospective cohort study of 57,053 men and women in Denmark. Scand J Public Health 35(4):432–441CrossRefPubMedGoogle Scholar
  18. 18.
    Overvad K, Tjonneland A, Haraldsdottir J, Ewertz M, Jensen OM (1991) Development of a semiquantitative food frequency questionnaire to assess food, energy and nutrient intake in Denmark. Int J Epidemiol 20(4):900–905CrossRefPubMedGoogle Scholar
  19. 19.
    Tjonneland A, Overvad K, Haraldsdottir J, Bang S, Ewertz M, Jensen OM (1991) Validation of a semiquantitative food frequency questionnaire developed in Denmark. Int J Epidemiol 20(4):906–912CrossRefPubMedGoogle Scholar
  20. 20.
    Gjerstorff ML (2011) The Danish cancer registry. Scand J Public Health 39(7 Suppl):42–45CrossRefPubMedGoogle Scholar
  21. 21.
    Wurtz AM, Tjonneland A, Christensen J, Dragsted LO, Aarestrup J, Kyro C, Overvad K, Olsen A (2012) Serum estrogen and SHBG levels and breast cancer incidence among users and never users of hormone replacement therapy. Cancer Causes Control 23(10):1711–1720CrossRefPubMedGoogle Scholar
  22. 22.
  23. 23.
    Rothman KJ (2002) Measuring interactions. In: Rothman KJ (ed) Epidemiology; an introduction. Oxford University Press, Inc, New York, pp 168–180Google Scholar
  24. 24.
    Vandenbroucke JP, von Elm E, Altman DG, Gotzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M, Initiative S (2007) Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration. Epidemiology 18(6):805–835CrossRefPubMedGoogle Scholar
  25. 25.
    Bruun N, Fenger-Grøn M (2015) Prior A: measures of interaction contrast (biological interaction) - ic, ici and icp. In. Århus University, Department of Public Health - Institute of General Medical PracticeGoogle Scholar
  26. 26.
    Hosmer DW, Lemeshow S (1992) Confidence interval estimation of interaction. Epidemiology 3(5):452–456CrossRefPubMedGoogle Scholar
  27. 27.
    Simin J, Tamimi R, Lagergren J, Adami HO, Brusselaers N (2017) Menopausal hormone therapy and cancer risk: an overestimated risk? Eur J Cancer (Oxford, England: 1990) 84:60–68CrossRefGoogle Scholar
  28. 28.
    Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J, Writing Group for the Women's Health Initiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA 288(3):321–333CrossRefPubMedGoogle Scholar
  29. 29.
    Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix A, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S, Women's Health Initiative Steering Committee (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. Jama 291(14):1701–1712CrossRefPubMedGoogle Scholar
  30. 30.
    Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ et al (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 310(13):1353–1368CrossRefPubMedGoogle Scholar
  31. 31.
    Morch LS, Lokkegaard E, Andreasen AH, Kruger-Kjaer S, Lidegaard O (2009) Hormone therapy and ovarian cancer. JAMA 302(3):298–305CrossRefPubMedGoogle Scholar
  32. 32.
    Morch LS, Kjaer SK, Keiding N, Lokkegaard E, Lidegaard O (2016) The influence of hormone therapies on type I and II endometrial cancer: a nationwide cohort study. Int J Cancer 138(6):1506–1515CrossRefPubMedGoogle Scholar
  33. 33.
    Morch LS, Lidegaard O, Keiding N, Lokkegaard E, Kjaer SK (2016) The influence of hormone therapies on colon and rectal cancer. Eur J Epidemiol 31(5):481–489CrossRefPubMedGoogle Scholar
  34. 34.
    Barnes EL, Long MD (2012) Colorectal cancer in women: hormone replacement therapy and chemoprevention. Climacteric 15(3):250–255CrossRefPubMedGoogle Scholar
  35. 35.
    Lavasani S, Chlebowski RT, Prentice RL, Kato I, Wactawski-Wende J, Johnson KC, Young A, Rodabough R, Hubbell FA, Mahinbakht A, Simon MS (2015) Estrogen and colorectal cancer incidence and mortality. Cancer 121(18):3261–3271CrossRefPubMedGoogle Scholar
  36. 36.
    Hvidtfeldt UA, Tjonneland A, Keiding N, Lange T, Andersen I, Sorensen TI, Prescott E, Hansen AM, Gronbaek M, Bojesen SE et al (2015) Risk of breast cancer in relation to combined effects of hormone therapy, body mass index, and alcohol use, by hormone-receptor status. Epidemiology 26(3):353–361CrossRefPubMedGoogle Scholar
  37. 37.
    Keum N, Greenwood DC, Lee DH, Kim R, Aune D, Ju W, Hu FB, Giovannucci EL (2015) Adult weight gain and adiposity-related cancers: a dose-response meta-analysis of prospective observational studies. J Natl Cancer Inst 107(2).  https://doi.org/10.1093/jnci/djv088
  38. 38.
    Kyrgiou M, Kalliala I, Markozannes G, Gunter MJ, Paraskevaidis E, Gabra H, Martin-Hirsch P, Tsilidis KK (2017) Adiposity and cancer at major anatomical sites: umbrella review of the literature. Br Med J (Clin Res Ed) 356:j477CrossRefGoogle Scholar
  39. 39.
    VanderWeele TJ, Knol MJ (2014) A tutorial on interaction. Epidemiologic Methods 3(1):33–72Google Scholar
  40. 40.
    Zhou B, Yang L, Sun Q, Cong R, Gu H, Tang N, Zhu H, Wang B (2008) Cigarette smoking and the risk of endometrial cancer: a meta-analysis. Am J Med 121(6):501–508 e503CrossRefPubMedGoogle Scholar
  41. 41.
    Ruan X, Mueck AO (2015) Impact of smoking on estrogenic efficacy. Climacteric 18(1):38–46CrossRefPubMedGoogle Scholar
  42. 42.
    Zhou Y, Jorgensen EM, Gan Y, Taylor HS (2011) Cigarette smoke increases progesterone receptor and homeobox A10 expression in human endometrium and endometrial cells: a potential role in the decreased prevalence of endometrial pathology in smokers. Biol Reprod 84(6):1242–1247CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    van Kruijsdijk RC, van der Wall E, Visseren FL (2009) Obesity and cancer: the role of dysfunctional adipose tissue. Cancer Epidemiol Biomark Prev 18(10):2569–2578CrossRefGoogle Scholar
  44. 44.
    Oyesanmi O, Snyder D, Sullivan N, Reston J, Treadwell J, Schoelles KM (2010) Alcohol consumption and cancer risk: understanding possible causal mechanisms for breast and colorectal cancers. Evid Rep Technol Assess 197:1–151Google Scholar
  45. 45.
    Friedenreich CM, Orenstein MR (2002) Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 132(11 Suppl):3456s–3464sCrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Unit of Diet, Genes, and EnvironmentDanish Cancer Society Research CenterCopenhagenDenmark
  2. 2.Department of Public Health, Section for EpidemiologyAarhus UniversityAarhusDenmark
  3. 3.Department of Breast SurgeryCopenhagen University Hospital HerlevCopenhagenDenmark

Personalised recommendations